First year at the LégiaPark
On March 12th, Amyl Therapeutics celebrated its first year at the LégiaPark. Since the move, Amyl has grown to 9 team members, and welcomed Chiara, Damien, Sophia, Sandra and Dafni. Our team is growing, and our projects are evolving, primarily in the field of Alzheimer’s disease. We are dedicated to find an efficacious and safe […]
Bio-Neuroscience
Amyl Therapeutics had joined Bio-Neuroscience, a premier partnership and investment summit for the world’s leaders in drug discovery and development in the field of central nervous system (CNS) neuroscience. It took place from February 25 to 27, 2025 in Amsterdam. A great opportunity to connect with key people in neuroscience. We are eager to take […]
Merry Christmas from the Amyl Team
The Amyl Team wishes you a Merry Christmas and a Happy New Year 2025 ! As 2024 is ending, we want to express our gratitude to our partners, investors, and collaborators. 2024 has been a year of challenges and major changes for us, driving innovation and progress in our research on neurodegenerative diseases. In 2025, […]
The Amyl Team – Who does what ?
Pierre Vandepapelière – CEO “As the CEO of Amyl Therapeutics, my role is to lead with vision, passion, and purpose. In a field as challenging as neurodegeneration, every decision brings us closer to potential breakthroughs that could one day impact the lives of patients, families, and communities. I’m proud to lead a team that’s committed […]
Bio-Europe Fall in Stockholm
We are excited to announce that Pierre Vandepapeliere, our CEO and Damien Toulorge, our Chief Scientific Officer, will be attending BioEurope 2024. This premier event brings together leaders in the biopharmaceutical industry to discuss innovation, partnership opportunities, and the future of biotech. We look forward to engaging with fellow professionals, sharing insights, and exploring collaborations […]
Team Building Event & Leadership Transition Announcement
We are pleased to share the success of our recent team-building event, which took place in the heart of historic Liège. The day offered a valuable opportunity for our team to strengthen their bonds and collaborate. We extend our gratitude to the entire team for their positivity and dedication throughout the day. This occasion also […]
1st International AL Amyloidosis meeting
We had the pleasure of attending the First International AL Amyloidosis Meeting in Brussels on July 5-6, 2024. This two-day program offered a unique opportunity to explore all aspects of AL amyloidosis, with a particular focus on managing complications related to organ involvement. The event also provided valuable moments for patients and medical professionals to […]
2024 AD/PD conference
Amyl Therapetucs had joined the 2024 AD/PDconference in Lisbon to learn about progress with Immunotherapeutics targeting abeta, TAU and alpha syn and also to consolidate exciting collaborations with research and development teams involved in in vitro and exvivo assays and models in neurodegenerative diseases. Exciting time! Connect
Amyl Therapeutics receives additional €5M funding to advance therapeutic platform
Investor base strengthened by Mr Evren Ucok joining as new shareholder and continued support from historical investors. Financing will be used to accelerate development of Amyl technology platform to treat neurodegenerative diseases and AL amyloidosis Amyl Therapeutics, a preclinical stage biotechnology company developing an amyloid specific technology platform to treat diseases linked to amyloid fibrils, […]
Amyl Team at the International Society on Amyloidosis (ISA) 2022
We are proud to announce that the Amyl team participated in the ISA (International Society on Amyloidosis) 2022 conference, presenting a poster that highlights our latest advancements on amyloidosis disease research. The team had the opportunity to engage with leading scientists and industry experts, sharing our insights and learning from the brightest minds in the […]